文献速递类风湿关节炎

托法替布治疗1年对类风湿关节炎血管生成生物标志物的影响

Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

30例RA患者接受托法替布5mg或10mg每日两次治疗并随访12个月,最终26例完成分析。治疗1年显著降低IL-6、VEGF、bFGF、EGF、PlGF和CathK,升高Gal-3(P<0.05);bFGF、PlGF、NT-proBNP与PECAM-1在RF血清阳性患者中存在差异(P<0.05)。

要点

  • 托法替布治疗1年显著降低IL-6、VEGF、bFGF、EGF、PlGF和CathK,升高Gal-3(P<0.05)。
  • bFGF、PlGF和NT-proBNP在RF血清阳性患者中较高,PECAM-1较低(P<0.05)。
  • NT-proBNP、CXCL8和CathK与ccIMT相关(P<0.05),其在RA相关动脉粥样硬化中的作用需进一步评估。

核心结论

  • 托法替布治疗1年降低bFGF、PlGF或IL-6的产生,可能抑制滑膜和主动脉炎症。
  • NT-proBNP、CXCL8和CathK与ccIMT相关,但其在RA相关动脉粥样硬化中的作用需进一步评估。

研究设计与样本

  • 12个月随访研究,纳入30例接受托法替布5mg或10mg每日两次治疗的RA患者,最终26例完成研究并纳入数据分析。
  • 在基线、治疗开始后6个月和12个月检测血管生成细胞因子、生长因子等水平,并行超声评估血流介导的血管舒张、颈动脉内中膜厚度和颈-股动脉脉搏波速度,以及18F-氟脱氧葡萄糖-PET/CT评估滑膜和主动脉炎症。

主要发现

  • 托法替布治疗1年显著降低IL-6、VEGF、bFGF、EGF、PlGF和CathK,同时升高Gal-3(P<0.05)。
  • RF血清阳性患者中bFGF、PlGF和NT-proBNP水平较高,PECAM-1水平较低(P<0.05)。
  • TNF-α、bFGF和PlGF与治疗后滑膜炎症相关,主动脉炎症更依赖于IL-6和PECAM-1(PET/CT评估,P<0.05)。
  • 相关分析中,NT-proBNP、CXCL8和CathK变量与ccIMT相关(P<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出NT-proBNP、CXCL8和CathK在RA相关动脉粥样硬化中的作用需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cardiovascular (CV) morbidity and mortality, and perpetuated synovial angiogenesis have been associated with RA. In our study we evaluated angiogenic factors in relation to vascular inflammation and function, and clinical markers in RA patients undergoing 1-year tofacitinib therapy. METHODS: Thirty RA patients treated with either 5 mg or 10 mg twice daily tofacitinib were included in a 12-month follow-up study. Eventually, 26 patients completed the study and were included in data analysis. Levels of various angiogenic cytokines (TNF-α, IL-6), growth factors [VEGF, basic fibroblast (bFGF), epidermal (EGF), placental (PlGF)], cathepsin K (CathK), CXC chemokine ligand 8 (CXCL8), galectin-3 (Gal-3) and N-terminal prohormone brain natriuretic peptide (NT-proBNP) were determined at baseline, and at 6 and 12 months after initiating tofacitinib treatment. In order to assess flow-mediated vasodilation, common carotid intima-media thickness (ccIMT) and carotid-femoral pulse-wave velocity, ultrasonography was performed. Synovial and aortic inflammation was also assessed by 18F-fluorodeoxyglucose-PET/CT. RESULTS: One-year tofacitinib therapy significantly decreased IL-6, VEGF, bFGF, EGF, PlGF and CathK, while it increased Gal-3 production (P < 0.05). bFGF, PlGF and NT-proBNP levels were higher, while platelet-endothelial cell adhesion molecule 1 (PECAM-1) levels were lower in RF-seropositive patients (P < 0.05). TNF-α, bFGF and PlGF correlated with post-treatment synovial inflammation, while aortic inflammation was rather dependent on IL-6 and PECAM-1 as determined by PET/CT (P < 0.05). In the correlation analyses, NT-proBNP, CXCL8 and Cath variables correlated with ccIMT (P < 0.05). CONCLUSIONS: Decreasing production of bFGF, PlGF or IL-6 by 1-year tofacitinib therapy potentially inhibits synovial and aortic inflammation. Although NT-proBNP, CXCL8 and CathK were associated with ccIMT, their role in RA-associated atherosclerosis needs to be further evaluated.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kerekes G, Czókolyová M, Hamar A, et al. Effects of 1-year tofacitinib therapy on angiogenic biomarkers in rheumatoid arthritis. Rheumatology (Oxford). 2023. PMID: 37871914. doi:10.1093/rheumatology/kead502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。